[{"address1": "3160 Porter Drive", "address2": "Suite 250", "city": "Palo Alto", "state": "CA", "zip": "94304", "country": "United States", "phone": "650 391 9740", "website": "https://bridgebio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.", "fullTimeEmployees": 550, "companyOfficers": [{"maxAge": 1, "name": "Dr. Neil  Kumar Ph.D.", "age": 44, "title": "Co-Founder, CEO & Director", "yearBorn": 1979, "fiscalYear": 2023, "totalPay": 1534840, "exercisedValue": 0, "unexercisedValue": 51135260}, {"maxAge": 1, "name": "Dr. Charles J. Homcy M.D.", "age": 75, "title": "Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director", "yearBorn": 1948, "fiscalYear": 2023, "totalPay": 563200, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Frank P. McCormick Ph.D.", "age": 73, "title": "Co-Founder, Chairman of Oncology & Director", "yearBorn": 1950, "fiscalYear": 2023, "totalPay": 542778, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Brian C. Stephenson C.F.A., Ph.D.", "age": 42, "title": "CFO & Secretary", "yearBorn": 1981, "fiscalYear": 2023, "totalPay": 1151240, "exercisedValue": 0, "unexercisedValue": 16193392}, {"maxAge": 1, "name": "Dr. Richard H. Scheller Ph.D.", "age": 70, "title": "Chairman of Research & Development", "yearBorn": 1953, "fiscalYear": 2023, "totalPay": 509622, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Thomas  Trimarchi Ph.D.", "title": "President & COO", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Uma  Sinha Ph.D.", "age": 65, "title": "Chief Scientific Officer", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 1313457, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Grace  Rauh", "title": "Vice President of Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Eli M. Wallace Ph.D.", "age": 56, "title": "Chief Scientific Officer of Oncology", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Eric Michael David J.D., M.D., Ph.D.", "age": 51, "title": "Chief Executive Officer of Gene Therapy", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 2, "boardRisk": 9, "compensationRisk": 7, "shareHolderRightsRisk": 9, "overallRisk": 8, "governanceEpochDate": 1730419200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 24.11, "open": 24.3, "dayLow": 22.92, "dayHigh": 24.3, "regularMarketPreviousClose": 24.11, "regularMarketOpen": 24.3, "regularMarketDayLow": 22.92, "regularMarketDayHigh": 24.3, "beta": 1.086, "forwardPE": -7.137419, "volume": 2780480, "regularMarketVolume": 2780480, "averageVolume": 2020846, "averageVolume10days": 1837130, "averageDailyVolume10Day": 1837130, "bid": 17.28, "ask": 23.78, "bidSize": 200, "askSize": 900, "marketCap": 4482842624, "fiftyTwoWeekLow": 21.62, "fiftyTwoWeekHigh": 44.32, "priceToSalesTrailing12Months": 20.58569, "fiftyDayAverage": 25.5002, "twoHundredDayAverage": 27.527124, "currency": "USD", "enterpriseValue": 5957793280, "profitMargins": -2.01529, "floatShares": 128174774, "sharesOutstanding": 188990000, "sharesShort": 17199451, "sharesShortPriorMonth": 18628832, "sharesShortPreviousMonthDate": 1727654400, "dateShortInterest": 1730332800, "sharesPercentSharesOut": 0.0915, "heldPercentInsiders": 0.05401, "heldPercentInstitutions": 0.94456, "shortRatio": 10.93, "shortPercentOfFloat": 0.1408, "impliedSharesOutstanding": 188990000, "bookValue": -6.508, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -438860000, "trailingEps": -2.42, "forwardEps": -3.06, "enterpriseToRevenue": 27.359, "enterpriseToEbitda": -11.684, "52WeekChange": -0.18878251, "SandP52WeekChange": 0.29098952, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "BBIO", "underlyingSymbol": "BBIO", "shortName": "BridgeBio Pharma, Inc.", "longName": "BridgeBio Pharma, Inc.", "firstTradeDateEpochUtc": 1561642200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "d3adccf0-6693-305c-9651-8da79033d61c", "messageBoardId": "finmb_412911458", "gmtOffSetMilliseconds": -18000000, "currentPrice": 23.72, "targetHighPrice": 70.0, "targetLowPrice": 36.7, "targetMeanPrice": 47.04375, "targetMedianPrice": 45.5, "recommendationMean": 1.61111, "recommendationKey": "buy", "numberOfAnalystOpinions": 16, "totalCash": 266324000, "totalCashPerShare": 1.409, "ebitda": -509903008, "totalDebt": 1729748992, "quickRatio": 1.932, "currentRatio": 3.193, "totalRevenue": 217764992, "revenuePerShare": 1.194, "returnOnAssets": -0.48883, "freeCashflow": -365117120, "operatingCashflow": -450219008, "revenueGrowth": -0.332, "grossMargins": 0.98902, "ebitdaMargins": -2.34153, "operatingMargins": -68.49524, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-11-16"}]